RxDoctor Payments Data

Jerry Ellington

Optometrist · Henderson, NCNPI 1740214188

Payments from drug & device makers

$1,009in general payments, 2019–2025

Across 19 payments — averaging $53.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$316
  • AbbVie$238
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$217
  • Kala Pharmaceuticals, Inc.$102
  • Sun Pharmaceutical Industries Inc.$84
  • Carl Zeiss Meditec AG$19
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$98998%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,009 in reported general payments places this provider in the 45th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$94,999
Medicare patients
507
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$49,336
Fluorometholone313$23,297
LumiganBimatoprost49$14,697
Travoprost48$6,926
Cyclosporine15$6,363
SimbrinzaBrinzolamide/Brimonidine Tart26$6,124
Latanoprost557$5,728
Prednisolone Acetate129$5,026
AlrexLoteprednol Etabonate15$4,415
Tobramycin-DexamethasoneTobramycin/Dexamethasone67$3,100
Loteprednol Etabonate27$2,925
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat151$2,315
Azelastine Hcl72$2,099
Dorzolamide Hcl88$1,712
Difluprednate19$1,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$238$64,033109 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate$217$7,34042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Henderson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →